Frontiers in Cell and Developmental Biology (Sep 2020)

Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression

  • Panxia Wang,
  • Rui Lan,
  • Zhen Guo,
  • Sidong Cai,
  • Junjian Wang,
  • Quan Wang,
  • Zeyu Li,
  • Zhenzhen Li,
  • Qianqian Wang,
  • Jingyan Li,
  • Zhongkai Wu,
  • Jing Lu,
  • Jing Lu,
  • Jing Lu,
  • Peiqing Liu,
  • Peiqing Liu,
  • Peiqing Liu

DOI
https://doi.org/10.3389/fcell.2020.548605
Journal volume & issue
Vol. 8

Abstract

Read online

Jumonji domain-containing 3 (JMJD3) protein, a histone demethylase protein, specifically catalyzes the demethylation of H3K27 (H3K27me3) and regulates gene expression. Sestrin2 (SESN2), a stress-inducible protein, protected against doxorubicin (DOX)-induced cardiomyopathy by regulating mitophagy and mitochondrial function. Here, the expression of JMJD3 was increased and that of SESN2 was decreased in both the heart samples from patients with dilated cardiomyopathy and chronic DOX-stimulation induced cardiomyopathy. Inhibition or knockdown of JMJD3 attenuated DOX-induced cardiomyocytes apoptosis, mitochondrial injury and cardiac dysfunction. However, JMJD3 overexpression aggravated DOX-induced cardiomyopathy, which were relieved by SESN2 overexpression. JMJD3 inhibited the transcription of SESN2 by reducing tri-methylation of H3K27 in the promoter region of SESN2. In conclusion, JMJD3 negatively regulated SESN2 via decreasing H3K27me3 enrichment in the promoter region of SESN2, subsequently inducing mitochondrial dysfunction and cardiomyocytes apoptosis. Targeting the JMJD3-SESN2 signaling axis may be a potential therapeutic strategy to protect against DOX-mediated cardiomyopathy.

Keywords